Informa plc (INF.L) – What Are Researchers Saying About This Stock?

Shares of Informa plc (LON:INF) have received an average rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is GBX 1,160.

Several research analysts have recently issued reports on INF shares. Berenberg Bank restated a “buy” rating and issued a GBX 1,040 price target on shares of Informa in a research report on Thursday, October 8th. Citigroup upped their price objective on Informa from GBX 990 to GBX 1,090 and gave the company a “buy” rating in a report on Wednesday, August 12th. JPMorgan Chase & Co. cut their target price on Informa from GBX 1,300 to GBX 1,285 and set an “overweight” rating on the stock in a research note on Thursday, July 2nd. Finally, Deutsche Bank Aktiengesellschaft increased their target price on Informa from GBX 1,140 to GBX 1,290 and gave the company a “buy” rating in a research note on Friday, October 9th.

Informa Price Performance

Shares of INF stock opened at GBX 861.60 on Wednesday. The firm’s 50 day moving average price is GBX 889.67 and its two-hundred day moving average price is GBX 859.66. The company has a debt-to-equity ratio of 64.99, a quick ratio of 1.70 and a current ratio of 0.55. Informa has a 52-week low of GBX 719 and a 52-week high of GBX 1,000. The stock has a market cap of £10.76 billion, a PE ratio of 50.39, a PEG ratio of 0.75 and a beta of 0.71.

Informa (LON:INF) last issued its earnings results on Thursday, July 30th. The company reported GBX 26.70 EPS for the quarter. Informa had a net margin of 5.43% and a return on equity of 3.90%. As a group, analysts forecast that Informa will post 59.32 EPS for the current year.

About Informa

Our events, digital products and academic research services connect specialists with knowledge, helping them learn more, know more and do more.

We do this in dozens of specialist markets and subject matter categories, including in Healthcare & Pharma, Technology, Finance, Education, Marketing, Health & Nutrition, Foodservice, and many more.

And we do this through a range of products and services, including major live events, specialist media and content, expert research articles, books and open research platforms, accredited training, buyer discovery services, and digital demand and lead-generation services.